Companies
Grifols
the Triturus immunoassay analyzer automates ELISA-format testing, positioned within Grifols's broader blood-and-plasma diagnostics portfolio alongside its immunohematology sample-processing systems.
- Country
- Spain
- Ticker
- NASDAQ:GRFS
NASDAQ:GRFS
Commercial
Coverage
| CN | EU | US | |
|---|---|---|---|
| analytics-pat | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | EUR 7.52 billion in 2025 | grifols.com |
| Headcount | more than 23,800 employees | albus-awards.com · grifols.com |
| Production site | manufacturing locations in the U.S., Spain, and other international regions | grifols.com · zh.grifolscn.com.cn |
| Capacity | 22 million liters/year fractionation capacity, aiming for 26 million liters/year by 2026 | grifols.com |
| Regulatory approval | FDA-licensed facilities and products, including albumin and various diagnostic reagents and systems | grifols.com |
| Certification | ISO 14001-certified environmental management system for main production facilities | grifols.com |
Independent sources: albus-awards.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Automated ELISA analyzers | analytics-pat | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.